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Abstract
This chapter aims at studying the microbial virulence determinants and markers 
of Helicobacter pylori (Hp), the molecular diagnostic of Hp, the growing antibiotic 
resistance with the related problem of heteroresistance, the genotypic resistance 
to antimicrobials compared with the phenotypic methods and the new treatment 
strategies for Hp eradication also evaluating new antimicrobial agents (furazoli-
done, vonoprazan). The virulence markers cover an important area in Hp pathology 
due to the correlation between these and the different diseases. The Hp molecuar 
diagnosis is fast, accurate and reliable over the traditional methods that are 
expensive and time- consuming. Therapy regimens used over the past decade are 
declining in efficacy being the Hp treatment bedevilled by drug-resistant strains. 
New treatment strategies are under study worldwide. The determination of the 
genetic resistance to antibiotics is very useful when used directly on gastric biopsies 
for prediction of antibiotics ineffectiveness or for addressing changes in previous 
treatments.
Keywords: Helicobacter pylori infection, virulence markers, molecular diagnostic, 
heteroresistance, antibiotic resistance, updated treatment strategies
1. Introduction
Helicobacter pylori (Hp) was first isolated in culture media by Warren and 
Marshall in 1983. Since then much progress has been made regarding all the char-
acteristics, the pathology and the resistance to antibiotics of this microorganism, 
However the history of this bacterium goes back a long time ago. In 1892 Bizzozzero 
described the presence of helical microorganisms in gastric mucosa of dogs and 
cats. In 1896 Salomon demonstrated the transmission to rats. In 1899 Iaworski & 
Krientis evidenced helicoidal microorganisms in human gastric biopsies. In 1967 
Luck, in 1975 Steer, in 1979 Fung and in 1982 Gregory showed the bacterial ultra-
structural morphology. In 1983 Marshall & Warren identified for the first time Hp 
[1]. In 1984 Langenberg hypothesized a relationship between stomach urease and 
spiral germs [2].
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Hp is a Gram-negative, spiral-shaped bacterium, with positive findings for 
urease, oxidase and catalase. It colonizes the human gastric epithelium. The 
main pathologies related to Hp infection are the following: chronic active gas-
tritis, peptic ulcer disease, gastric carcinoma and mucosa-associated lymphoid 
tissue (MALT) lymphoma. Further, epidemiological and eradication studies 
have demonstrated a casual relationship between Hp infections and endothelial 
dysfunction, leading to vascular diseases [3, 4]. Generally, the colonization 
occurs primarily during childhood especially in the developing areas, usually in 
the same family for a cohort effect [5]. This colonization is widely asymptomatic 
even if a long-lasting infection can be established in some subjects. After colo-
nization all patients with H. pylori infection develop histological gastritis, which 
corresponds to classical chronic gastritis and is characterized by the infiltration 
of neutrophils and other inflammatory cells. However, most patients are asymp-
tomatic for life, while few of them will develop a digestive disease. Infection is 
virtually lifelong in the absence of treatment, implying that evasion of the host 
response is efficient.
Hp infection is widespread with about 50% of world population infected. In 
developing countries, especially in lower socioeconomic classes, the prevalence 
is higher (about 80%), whereas in the developed areas such as the USA, Canada, 
Japan, and Western Europe, the prevalence is much lower (about 25–30%) [6–9].
The infection outcome mainly depends on three factors: strain virulence, host 
response and environmental factors. The strain pathogenicity depends on the 
virulence markers present in the bacterium. Host response shows the peculiarity 
that it is not protective, indeed in some cases may worsen the patients situation. 
Environmental factor, such as cigarette smoking is a major risk factor for duodenal 
ulceration among Hp-infected persons. Other important factors include stress, 
childhood living conditions, diet, alcohol and NSAIDs (non- steroidal anti-inflam-
matory drugs) use [10, 11].
Aim of this chapter was to study the virulence markers involved in the patho-
genicity of Hp such as Vacuolating cytotoxin (VacA) and vacA gene (vacuolating 
cytotoxin gene A), intermediate region (i) of vacA, CagA protein and the cag 
pathogenicity island. The molecular diagnostic of the microorganism, the genotypic 
resistance related to the phenotypic one, the antibiotic resistance and the updated 
treatment strategies including also non-antibiotics therapy are similarly studied.
2. Pathogenicity and virulence markers
2.1 Pathogenicity
The pathogenicity of Helicobacter pylori is shown in Figure 1.
Here it is reported the course of Hp infection in the patients beginning from 
the childhood to the advanced age considering what may happen at high level or at 
low level of acidity. The infection starts with the colonization of the microorgan-
ism in the normal gastric mucosa which can lead to an acute Hp infection at a low 
level of acid production. This in turn can result in a chronic Hp infection which 
may be asymptomatic for a lifetime or produce a non- atrophic pangastritis which 
can lead to MALT lymphoma. At high level of acidity the infection can result in an 
antral predominant gastritis with an evolution to duodenal ulcer. At a low level of 
acidity it can result in a corpus predominant atrophic gastritis which may evolve in 
gastric ulcer, intestinal metaplasia, dysplasia and gastric cancer in 2% of infected 
patients [12].
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2.2 Markers of virulence
Gastric colonization is a prerequisite for Hp-associated disease and this is 
mediated by both flagella and urease: mutant strains lacking these features cannot 
establish infection. The most important determinants of virulence are the following: 
(a) Vacuolating cytotoxin (VacA) and vacA gene (vacuolating cytotoxin gene A), (b) 
Intermediate region (i) of vacA, (c) CagA protein and the cag pathogenicity island, 
(d) Hps60 superficial protein, (e) BabA adhesion, (f) Urease virulence determinant.
2.2.1 Vacuolating cytotoxin (VacA) and vacA gene
This is a protein found in culture supernatant that induces vacuolation in a 
variety of cultured epithelial cell lines, The expression of Hp vacA gene leads to the 
production of a vacuolating cytotoxic protein VacA, (present only in about 40% of 
isolates), which is responsible for inducing the formation of acidic vacuoles. This 
secreted protein toxin is responsible for the gastric epithelial erosion observed in 
infected hosts [13].
In Figure 2 the schematic structure of Vac A is reported [10].
In this figure the mosaicism of VacA is underlined [13]. In fact the vacA gene 
contains two variables regions: the s- (signal) region encoding part of the signal 
peptide with the N-terminus of the mature protein (hydrophilic part) and the m- 
(middle) region encoding C-terminal portion of the final processed polypeptide 
(hydrophobic part). These regions are both cleaved upon secretion to yield a mature 
toxin monomer of 87–95 kilodaltons [14]. The combination between the s and m 
regions causes the strains virulence and is correlated with the kind of disease. In fact 
s1-type strains are associated with vacuolating activity, s2-type is non-vacuolating, 
m-region causes the specificty of cell vacuolating: m1 alleles are more toxigenic than 
strains with m2 alleles, vacA s1m1 is the most toxigenic combination and is associ-
ated with duodenal and gastric ulceration.
Figure 1. 
Pathogenicity of Helicobacter pylori. From Suerbaum et al. [11].
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The subtype s1a m1 is the most virulent strain involved in patients with ulcer.
A further region of the vacA gene (i- intermediate region) has been reported in 
literature to be associated with gastric cancer [15].
2.2.2 CagA protein and the cag pathogenicity island
Cag pathogenicity island is a chromosomal region with about 37,000 bp and 29 
genes. Four genes are similar to the components of the type IV secretion system. 
Proteins encoded by the island are involved in two major processes: the induction 
of interleukin-8 production by gastric epithelial cells and the translocation of CagA 
Figure 3. 
The Cag pathogenicity Island. Modified by Suerbaum et al [11].
Figure 2. 
The protein VacA. From Atherton et al [10].
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from the bacterium into the host cell by forming a syringe and a needle apparatus 
that delivers CagA protein (a protein of about 1200 amino-acids whose size varies 
between strains). Some genes are essential for the induction of interleukin-8; other 
genes are required for the translocation of CagA. The cagA-positive strain increases 
the risk of athrophic gastritis development and mucosal inflammation [16]. (see 
Figure 3).
2.2.3 Heat shock proteins (Hsps) or stress proteins
Hsps are families of highly conserved proteins serving as a strong antigenic tar-
get for the immune response linked with pathology. H. pylori produces 2 Hsps: a gro 
Es-like HspsA (size 13 kd) and a gro E1-like HspsB (size 54–60 kd). Hsp60 is shared 
by H.pylori and eukariotic cells (autoimmune response) [17, 18]. The role of heat-
shock proteins in immune reactions is complex especially for the cellular effects 
of this proteins during the recognition processes by innate immunity. Heat-shock 
proteins (HSPs) are expressed at high levels by bacterial pathogens during adapta-
tion to intracellular survival. The Hsps of both pathogens and hosts are involved in 
the activation of the receptors in innate immune response and in the presentation of 
antigens for the adaptive immune response [17, 18].
2.2.4 Bab A adhesions
The microorganism needs of adhesins for beginning its infective process. The 
presence of bacterial adhesins devoted to the attachment to human gastric epithe-
lium, is essential [19]. Helicobacter pylori adherence to the human gastric mucosa 
involves specific bacterial adhesins and cognate host receptors. babA gene codes for 
the blood group antigen-binding adhesin BabA whereas the babB product is associ-
ated with a non-binding phenotype. BabA major adhesin is directed to the fucosyl-
ated Lewis b blood group antigen not present in all kinds of gastric cells [19].
2.2.5 Urease virulence determinants
The enzymatic activity of urease manages to break the urea molecule in bicar-
bonate ion and ammonia so that it is able to neutralize the gastric acid and is also 
correlated with the dual function of adhesivity and immunogenicity. The urease 
binds to the CD74 receptors of gastric epithelial cells [20]. It can be suggested that 
urease is specifically important for the attachment of Hp and for the pro-inflam-
matory immune response initiated by the bacterium. The binding of the subunit 
urease B to CD74 expressed on gastric cells may therefore contribute to increase the 
bacterial virulence during infection [20].
3. Molecular diagnostic of Helicobacter pylori
Helicobacter pylori is a fastidious bacterium difficult to grow in the common 
media culture. Essential conditions for Hp culture were the following: microaero-
philic atmosphere, temperature of 37° (range 33°-40°), presence of 0.5% glycine. 
The appropriate culture medium such as Pylori Selective Agar (bio-Merieux, Marcy 
L’Etoile France) contains 5% sheep blood and antibiotics (amphotericin, vancomy-
cin and trimethoprim). The incubation lasts 10 days under CO2 atmosphere. This 
method is complicated, expensive and time-consuming so that when the isolation 
of the strain is unnecessary, the molecular method is very useful for its rapidity and 
appropriateness.
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Helicobacter pylori presence in gastric specimens can be assessed by various 
methods including molecular PCR assay (GenoType HelicoDR kit) [21]. PCR is 
a more sensitive method (84.3% sensitivity, 75.0% specificity), with a higher H. 
pylori detection rate compared to culture [22].
Tissue obtained from gastroscopic biopsy was minced using a sterile scalpel, 
lysed by tissue lysis buffer and proteinase-K enzyme (Bioneer, Daejeon, Korea), 
and incubated for 10 min at 60°C. Ten total DNA was extracted with an AccuPrep 
Genomic DNA Extraction Kit (Bioneer, Daejeon, Korea). This kit contains a glass 
filter in a column tube that can bind efficiently to DNA in the presence of salts. 
Additional washing steps were performed for proteins and salt removal. Aliquots of 
50 μL were used for PCR amplification as reported elsewhere [23].
Molecular methods such as PCR offer marginal improvements when done on 
biopsy material, but have the advantage of being able to accurately identify H. pylori 
in areas outside the stomach where cultures usually fail. PCR can detect low num-
bers of organisms in gastric juice, bile, stool and oral secretions. Because of its high 
sensitivity it can also be used for epidemiologic investigations of environmental 
sources [24]. Molecular methods have been used in variable specimens other than 
gastric mucosa [25].
4. Antibiotic resistance and heteroresistance
4.1 Antibiotic resistance
The antibiotics once regarded as the first choice for Hp infection (such as 
metronidazole and clarithromycin), included in all therapeutic regimens, are now 
declining in efficacy because of their extensive use in many areas for unrelated 
infections. Metronidazole (MZ) mostly showed a very high resistance worldwide 
achieving a level up to 78.2% in China [26]. Clarithromycin (CLA) resistance rates 
have currently reached high levels, such as 30% in Italy and Japan, 40% in Turkey, 
and more than 70% in China, although rates in Sweden, Taiwan, and Germany are 
lower [27]. CLA was once considered the most powerful antibiotic for Hp infec-
tion. The local pattern of Hp resistance to CLA results as being crucial in each area, 
considering that in countries where CLA resistance is above 15–20%, this drug 
should not be used. CLA-resistant Hp has been extensively studied: its prevalence 
has become increasingly higher in many geographical areas. Fluoroquinolone (the 
most common fluoroquinolone is Levofloxacin LEV) resistance has been increasing 
worldwide in recent years achieving 20% in Italy, 13.3% in Germany, and 19.2% 
in China [26, 28]. These data are especially important in those regions planning a 
levofloxacin-based therapy because resistance to fluoroquinolones generally shows 
a major impact on the success of treatment [29].
In a study conducted in an Academic Hospital in Rome by our group on 80 Hp 
strains isolated from 80 biopsy samples in infected patients, the resistance percent-
age measured phenotypically through MIC values to MZ, CLA, LEV, TE (tetracy-
cline) and AMX (amoxicillin) resulted as follows: 61.6% (50/80), 35% (28/80), 
20% (16/80), 2.5% (2/80), and 1.25% (1/80), respectively. The MICs (Minimum 
Inhibitory Concentrations) resulted as being very high mainly to MZ showing three 
strains with MIC = 256 μg/mL and to CLA showing four strains with MIC rang-
ing from 64 μg/mL to 128 μg/mL. As for LEV the MIC ranged from 0.25 μg/mL to 
32 μg/mL (only one strain showed a MIC equal to 32 μg/mL) [30].
Multidrug resistance (the contemporaneous resistance to two or more antibiotics) 
is reported in Figure 4 .
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4.2 Heteroresistance (HR)
Heteroresistance is defined as the concomitant presence of a different suscepti-
bility pattern in the different districts of a single stomach in the same patient [31]. 
This is a common occurrence in Hp population and can be explained either as the 
result of multiple infections (unrelated isolates) or as the presence of susceptible 
Figure 4. 
Characteristics of phenotypic antibiotic resistance in Helicobacter pylori strains. From Mascellino et al. 
[30]. Notes: Proportion of phenotypic resistant Helicobacter pylori isolates (%) to the respective antibiotics 
in an Academic Hospital in Rome (Italy). Abbreviations: MZ: metronidazole; CLA: clarithromycin; LEV: 
levofloxacin; TE: tetracycline. Resistance belonging to the association CLA + MZ was the highest one being 
detected in 30% of samples (24/80), resistance to the combinations MEZ + LEV and CLA + LEV ranged 
between 13.75% (11/80) and 11.25% (9/80 strains) respectively. Only 6.25% samples (5/80) harbored the triple 
resistance MZ + CLA + LEV. As far as the dual combination MZ + TE is concerned, resistance was found just 
in one strain (1.25%). In China too, a similar trend of multidrug resistance of Hp is found [26]. In general, the 
antibiotic combinations consisting of MET, CLA and LEV had higher combined resistance rate, whereas the 
antibiotic combinations recommended in bismuth-containing quadruple therapy (Bismuth, Omeoprazole, MZ, 















































MZ-metronidazole, CLA-clarithromycin, AMX-amoxicillin, LEV-levofloxacin, TE-tetracycline S-susceptible, 
R-resistant, A-antrum, C-corpus, F-fundus.
*No growth.
Table 1. 
Heteroresistance of 5 strains (Mascellino, unpublished data).
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and resistant variants of the same strain (related isolates). In the latter case, HR has 
been described either as intra-district when susceptible and resistant isolates are 
present at the same time in the same site of gastric mucosa or as inter-district when 
multiple strains colonize different areas of the stomach [32, 33]. Heteroresistance of 
5 strains out of 80 considered above is reported in Table 1.
For each of these patients, we found a different antimicrobial pattern in the 
strains isolated from antrum (susceptible) and corpus/fundus (resistant) towards 
CLA (five patients), MZ (two patients), AMX (three patients), LEV (three 
patients) and TE (one patient). The strain genotypes, identified on the basis of 
virulence genes (cagA and vacA), were the same for both loci in pairs of isolates 
(susceptible and resistant) obtained from different regions (A,C and F) of a single 
stomach (cag + s1m2 in one patient, cagA+s1m1 in three patients and cagA s2m2 in 
one patient).
5. Phenotypic resistance versus genotypic resistance
The phenotypic resistance was calculated on the basis of MIC (Minimum 
Inhibitory Concentration) performed on the biopsy samples. Interpretation of sus-
ceptibility test results was performed in accordance with the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST 2020) recommendations [34]. 
In order to define strains resistance the following MIC breakpoints were used: 
S ≤ 0.125 μg/ml and R > 0.125 μg/ml for AMX; S ≤ 0.25 μg/ml and R > 0.5 μg/ml 
respectively for CLA; S ≤ 1 μg/ml and R > 1 μg/ml for both TE and LEV; S ≤ 8 μg/ml 
and R > 8 μg/ml for MZ.
The genotypic resistance is based on the point mutations present on the chromo-
some. Common resistance mechanisms to clarithromycin include point mutations 
in the bacterial domain V of 23S rRNA, which prevents antibiotic binding [35]. 
There are 3 point mutations in the 23S rRNA gene: A2143G, A2142G, and A2142C; 
these account for 90% of cases for primary resistance in Western countries [36]. 
Fluoroquinolone agents (mainly levofoxacin, which is a broad-spectrum quinolone) 
are an alternative therapy for infections caused by H. pylori and serve as second-line 
treatment [37]. Fluoroquinolone targets are the DNA gyrase, an enzyme responsible 
for negative supercoiling during the DNA replication process. This enzyme con-
tains two A subunits and two B subunits, encoded by gyrA and gyrB, respectively 
[38]. Resistance to clarithromycin and fuoroquinolones, which is mostly acquired 
through point mutations, can be detected by molecular techniques. GenoType 
HelicoDR (Hain Life Science, Germany) test is a molecular diagnostic method 
for easy and simultaneous detection of frequent point mutations responsible for 
clarithromycin and fuoroquinolones resistance [21].
Genotypic susceptibility testing can be also performed by a real-time PCR fol-
lowed by melting curve analyses using fluorochrome labeled hybridization probes 
for identifying the mutations on the 16S rRNA conferring resistance to TE [28].
5.1 Correlation between genotypic and phenotypic methods
The correlation between genotypic and phenotypic methods is reported in 
Table 2.
The PCR method results as being very useful in detecting the resistant strains in 
comparison with the E-test technique which primarily detects the susceptible ones. 
Mixed Hp infections were demonstrated only through the PCR in patients concomi-
tantly yielding both wild type and resistant strains in a single gastric region. The 
resistance with both methods (phenotypic tests and PCR molecular tests) for CLA 
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and TE demonstrated the superiority of PCR over the phenotypic test (data not 
shown). As for CLA, the resistance was detected in 76% (16/21) of patients by PCR 
and 57% (12/21) by E-test, whereas for LEV the same values corresponded to 83% 
(10/12) and 41% (6/12) respectively. In this last case the difference turned out to be 
statistically significant (p < 0.05).
The genotypic test performed directly on the biopsy samples shows some great 
advantages over the E-test. In fact the genotypic-resistance resulted very useful to 
identify mixed infections that represent a real problem possibly leading to a resis-
tance underestimation or in the case of absence of live bacteria (coccoid forms) 
or contamination. The real-time PCR detects the resistant population at a lower 
concentration than the phenotypic tests which primarily show susceptible bacteria. 
Following our results [30], the E-test is unable to detect all resistant strains because 
when there are many susceptible bacteria compared with the resistant ones, these 
susceptible bacteria are identified first leading to a misclassification. On the con-
trary through a direct examination of gastric samples by genetic tests, a diversity 
of strains (susceptible, resistant or both) can be detected at the same time. Mixed 
Hp infections were demonstrated in patients yielding both wild type and resistant 
strains in a single gastric region at the same time. The use of genotypic tests directly 
on the clinical specimens could predict the antibiotic resistance addressing changes 
in previous treatments or for evaluating the primary resistance to antibiotics (ie 
CLA) in order to avoid administration of ineffective antimicrobials [23, 38].
6. Antibiotic therapy
Therapy regimens used over the past decade are declining in efficacy being 
the Hp treatment affected by drug-resistant strains. New treatment strategies are 
under study worldwide. The knowledge of the local susceptibility to the antibiotics 
in a single geographical area is crucial in order to establish a correct therapy. For 
instance as far as CLA susceptibility is concerned, it is stated that in those regions 
that show a resistance percentage > 15%, this antibiotic should not be used [30]. 
Indeed it would be possible to predict the efficacy of any treatment knowing the 
prevalence of antibiotic resistance for a regimen or even for a specific patient. As a 
matter of fact empiric therapy that takes into consideration the regional and mostly 
the local resistance patterns may be superior to the tailored therapy in predict-
ing the efficacy of any regimen [40]. Hence, the regional resistance patterns and 
the eradication rates in the context of local environment are crucial for a correct 





PCR E-test PCR E-test
4 Wildtype + A2143G*




6 gyr A mutation
codon 87




16/21 R (76%) 12/21 R (57%) 10/12 R (83%) 6/12 R (41%)
S = susceptible, R = Resistant, A2143G = point mutation on CLA23SrRNA gene conferring resistance to CLA, 
gyrA = gene conferring resistance to LEV.
*Refers to mixed iinfections (from Mascellino et al. [39]).
Table 2. 
Correlation between genotypic and phenotypic methods.
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The old triple therapy (PPI=Proton Pump Inhibitors + clarithromycin and either 
amoxicillin or metronidazole) should be considered only in areas where the resis-
tance to CLA is low (<15%) or where a high eradication success with these regimens 
(>85%) is well known. In general, in Western countries, clarithromycin-containing 
triple and sequential therapy should be considered obsolete as empiric therapies.
The resistance to CLA is reported to be increasing all over the world, and in 
some countries, it depends on the local seropositivity rate [42]. As far as LEV is con-
cerned, there is a more limited number of studies evaluating susceptibility to LEV. 
In Italy LEV resistance has been reported to be 22–24% as well as in Portugal [43]. 
MZ shows a high rate of resistance (50–80%) in almost all the studied countries 
achieving a rate of 80% especially in developing areas [26]. Nevertheless in spite of 
its high resistance in vitro, it is included in the BQT (Bismuth Quadruple Therapy). 
This discrepancy between in vitro MZ resistance and treatment outcome may 
partially be explained by changes in oxygen pressure in the gastric environment, as 
MZ-resistant Hp isolates become MZ susceptible under low oxygen conditions in 
vivo [44]. The Bismuth Quadruple Therapy (PPI + Bismuth +MZ + TE] for 14 days 
has proven high efficacy in spite of MZ resistance in Europe bypassing also the 
quinolone resistance [29].
The new guidelines for the cure of Hp recommend to prolong the therapy from 
10 to 14 days [45]. As first line therapy a concomitant non-bismuth quadruple 
therapy (PPI + AMX + MZ + CLA) may be used in those countries where the resis-
tance to CLA is <15% otherwise the traditional bismuth quadruple therapy unaf-
fected by CLA resistance, should be used. The BQT (PPI + Bismuth+MZ + TE, 
PBMT) results as being very useful in the countries where particular Hp high 
resistance is detected and when the AST (Antimicrobial Susceptibility Testing) 
is complicated to perform. In contrast if a bismuth-based quadruple therapy is 
used in these different situations, it is not recommended to perform AST because 
a risk of having a TE-resistant strain is extremely low and it was shown that 
MZ-resistance has no impact in the treatment of patients [29]. Recommended 
rescue therapy includes LEV as a second line of treatment ie PPI, AMX, LEV 
(PAL) [45] these therapeutic options are reported in Table 3.
Recommendations Type of therapy Drug
First line • Old triple therapy*
• Concomitant non- bismuth  
quadruple therapy




Second line • Concomitant non bismuth quadruple 
therapy.
• BQT









Notes: The therapy should be prolonged for 14 days.
PPI = proton pump inhibitor, CLA = clarithromycin, MZ = metronidazole; TE = tetracycline; AMX = amoxicillin, 
RIF = rifabutin.
*Obsolete therapy.
**Used in the countries where CLA – resistance is <15%.
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7. New treatment strategies
Hp antibiotic resistance has been increasing all over the world in the last decade 
and this phenomenon constitutes an important challenge for the treatment of this 
fastidious bacterium. This has prompted the researchers to an obstinate search for 
new solutions such as the vaccine development and new treatments based on the 
use of natural resources such as plants, probiotics, and nutraceuticals [46, 47].
A new compound, a guanidine derivative bearing adamantane-1-carbonyl 
2-bromo-4,6-difluouro-phenyl substituents (H-BDF), seemed to be promising 
against the strains tested [48]. Other substances were studied against Hp such as 
three known and five unknown N-substitute-2-oxo- H-1-benzopyran-3- carbox-
amides (coumarin-3-carboxamides). The compounds with a 4-acyl-phenyl group 
showed the best activity against H. pylori metronidazole- resistant strains [49].
Non-traditional therapies have been indicated as a means to target this important 
gastric pathogen. This approach also includes the use of antimicrobial peptides (core 
component of innate immune system of numerous eukaryotes) that interact with the 
anionic Gram-negative cell wall because of charge electrostatic attractions [50]. It 
also seems reasonable to investigate other options aimed at reinforcing the immune 
system of these patients, The potential role of N-acetil-cysteine which is capable of 
destroying bacterial biofilm, is an emerging treatment for recalcitrant infections [51]. 
Vonoprazan (potassium-competitive acid blocker P-CAB) is a new compound which 
could improve eradication rates by raising the intragastric pH and thus increasing 
bacterial antibiotic susceptibility [52]. Recent studies revealed that P-CAB-based 
triple therapy was more effective than PPI-based triple therapy (76.1% versus 40.2%) 
as a first-line Hp eradication method [53]. Furthermore, even in the presence of CLA-
resistant strains, P-CAB-based triple therapy showed good eradication rates [52].
Furazolidone (FUR) is a new antibiotic studied mainly in China which has 
demonstrted a great activity either alone or in combination with other antibiot-
ics against H. pylori. It is a monoamine oxidase inhibitor which can interact with 
the metabolism of tyramine causing side-effects such as vomiting, diarrhea and 
nervous system disorders. In China, the FUR is available for the treatment of 
patients. Therefore, quadruple therapy with proton pump inhibitors, bismuth and 
a combination of two antibiotics specifically FUR, TET or AMX would be more 
suitable for Chinese patients [26]. This treatment is also recommended in the 
Maastricht V/Florence Consensus Report [29] the new treatment strategies are 
shown in Table 4.
Compounds Activity
Guanidine derivate Promising activity against Hp strains
Coumarin-3-carboxamides Activity against Hp-MZ--R
Antimicrobial peptides Interaction with Gram- neg cell wall
N-acetyl-cysteine Activity on the bacterial biofilm
Vonoprazan
(potassium competitive acid blocker)




PPI + bismuth+FUR+ either TE or AMX
Fur = Furazolidone, MZ = Metronidazole, TE = tetracycline, AMX = amoxicillin, R = Resistant.
*Used alone or in combination with other antibiotics (in western countries).
Table 4. 
New treatment strategies and non-traditional therapies.
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8. Conclusions
Helicobacter pylori is a complex microorganism that is difficult to cultivate, and 
treat also presenting particular characteristics of pathogenicity and virulence mark-
ers. Much progress has been made since 1983 when it was discovered first by Warren 
and Marshall [1] making it one of the most studied bacteria. Hp is well adapted to 
the human host as evidenced by its chronical persistence in the gastric niche and by 
the finding that the bacterial surface carries structures (antigens) which are identi-
cal to those found on human cells [54].
The markers of virulence such as CagA and VacA are seen to greatly influence the 
outcome of Hp infection. The combination of different virulence genotypes is the most 
important factor that strongly affects the bacterial virulence making some strains more 
pathogenic than others.
The heteroresistance is a big problem in the evaluation and management of 
Hp resistance in the infections. In fact the heteroresistance detected in five of 
our patients worsens the situation being an important issue as an isolate could be 
mistakenly considered susceptible if a single biopsy is used for antimicrobial tests 
possibly leading to a resistance underestimation [31].
The emergence of PCR method provides a quick, convenient way to guide 
tailored therapy in clinical practice of H. pylori [55]. In this situation without 
performing the susceptibility tests which are time-consuming and expensive, the 
gastroenterologists could establish a suitable treatment for Hp infected patients 
who in any case underwent a gastroscopy. The use of genotypic tests directly on 
the clinical specimens could predict the antibiotic resistance addressing changes in 
previous treatments. The real-time PCR detects the resistant population at a very 
low concentration not detectable by phenotypic tests which primarily show suscep-
tible bacteria. The genotypic-resistance is useful in case of absence of live bacteria, 
contamination or for identifying mixed infections.
The CLA-resistance levels and mainly the local susceptibility turn out to be 
crucial to establish a correct therapy. The quadruple therapy (BQT) with proton 
pump inhibitor, bismuth and a combination of two antibiotics, specifically MZ and 
TE then unaffected by CLA and LEV resistance, turns out to be appropriate in the 
Hp infected- patients resulting in an effective eradication rate.
The lack of data on local susceptibility patterns and on eradication success rates 
was identified as a knowledge gap that has a major impact on the choice of therapy 
and hence best management. Periodic susceptibility testing should be considered by 
health authorities and clinicians should be encouraged to record their successes.
All in all we can say that this microorganism since its discovery in 1983 by 
Marshall and Warren, has been deeply studied and considered one of the most 
important gastric pathogen involved in a wide range of pathologies other than the 
classical ones, such as cancer, atherosclerosis and endothelial dysfunction leading to 
vascular diseases.
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